Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHENA: AZD5851 GPC3-directed CAR-T in advanced hepatocellular carcinoma
jRCT2053250014Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- May 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
01
Overview
Phase 2, open-label, single-arm trial of AZD5851 in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Primary endpoint: Safety and tolerability of AZD5851. Planned start May 2025; status: not yet recruiting.
02
Drugs
AZD5851
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2053250014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053250014.